Syntheses of novel antitumor dihydroxanthone derivatives with inhibitory activity against DNA topoisomerase II

Bioorganic and Medicinal Chemistry Letters

Volumn 9, Issue 18, 1999, Pages 2653-2656

  Sato, Seiichi ^a   Suga, Yasuyo ^a   Yoshimura, Toshihiko ^a   Nakagawa, Ryusuke ^a   Tsuji, Takashi ^a   Umemura, Ken ^b   Andoh, Toshiwo ^b  

^a AJINOMOTO CO INC   (Japan)

^b SOKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DRUG ANALOG; XANTHONE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; TUMOR CELL LINE; TUMOR MODEL;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA TOPOISOMERASES, TYPE II; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; MICE; TUMOR CELLS, CULTURED; XANTHINES;

ANIMALIA; MURINAE;

EID: 0033588935     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00440-0     Document Type: Article

References (10)

1. 1. Wang, J. C. Annu. Rev. Biochem. 1985, 54, 665.
2. 2. Nidulalin A was originally isolated from Emericella nidulans. Kawahara, N.; Sekita, S.; Satake, M.; Udagawa, S.; Kawai, K. Chem. Pharm. Bull., 1994, 42, 1720.
3. 3. Sato, S.; Nakagawa, R.; Fudo, R.; Fukuda, Y.; Yoshimura, T.; Kaida, K.; Ando, T.; Kameyama, T.; Tsuji, T. J. Antibiot. 1997, 50, 614.
4. 4. Sato, S.; Fukuda, Y.; Nakagawa, R.; Tsuji, T.; Umemura, K.; Andoh, T. submitted.
5. 5. Fujimoto, H.; Sato, Y.; Yamaguchi, K.;Yamazaki, M. Chem. Pharm. Bull. 1998, 46, 1506.
6. 3) δ 12.22(1H, s), 7.40(1H, d, 7=5.6Hz), 6.43-6.46(2H, m), 6.29-6.32(2H, m), 4.57(1H, d, J=5.6Hz), 3.83(2H, m), 3.47(2H, m), 2.31(3H, s), 1.60-1.99(4H, m).
7. 7. The test compounds, including 1, 9a, 9b, and 9c, were incubated in plasma/DMSO(9/1, v/v) at 37°C for 2 hours. Then resulting solutions were analyzed by HPLC. HPLC was carried out on a column (Inertsil ODS-3, 0.6 i.d. × 15cm) with a linear gradient from 30% to 80% aqueous MeCN at a flow rate of 1 ml/min. The compound 4 showed no cytotoxic activity against HCT-116 human cancer cell line in vitro at a dose of 40μM.
8. 8. Ishii, K.; Hasegawa, T.; Fujisawa, K., Andoh, T. J. Biol. Chem. 1983, 258, 12728.
9. 9. Marini, J. C.; Miller, K. G.; Englund, P. T. J. Biol. Chem. 1980, 255, 4976.
10. 10. Fragments of Colon 26 tumor(10mg) were inoculated subcutaneously(sc) into CDF1 mice. Test compounds were given iv on day 7, 11, and 15. On day 17, the tumor weights were measured. The inhibition ratio was evaluated as (1-T/C)×100(%)(T; the mean tumor weight of the treated group, C; the mean tumor weight of the control group). Each group consisted of 5 mice.